Form 13F-HR TPG-Axon Capital Managem For: Sep 30 Nov 16, 2009 02:24PM

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6607414


TPG-Axon Bumps National City (NCC) Stake, Then Drops Below 5% Threshold Oct 2, 2008 03:42PM

In a 13G filing on National City Corporation (NYSE: NCC), TPG-Axon reported 3.86% stake (80,990,300 share) stake in the ...


TPG-Axon Capital Discloses 5.2% Stake in Arch Coal (ACI) Jul 25, 2008 04:32PM

In a 13G filing on today on Arch Coal (NYSE: ACI), TPG-Axon Capital disclosed a 5.2% stake in the coal company. The ...


Unusual 11 Mid-Day Movers 4/16: POZN, SORC, EXM, GRO Higher; TLB, HCSG, GLG, CDL Lower Apr 16, 2008 01:02PM

POZEN Inc. (Nasdaq: POZN) 34% HIGHER; GlaxoSmithKline (NYSE: GSK) and POZEN announced today that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines pioneered by GSK, and an anti-inflammatory pain reliever in a single tablet.

Source Interlink Companies, Inc. (Nasdaq: SORC) 25.5% HIGHER; reports Q4 EPS of $0.20, versus $0.18 last year. Revenues for the quarter rose 47.3% to $706.4 million, versus the consensus of $602.5 ...


Pre-Open Movers 4/16: POZEN (POZN) Surges On FDA Approval; Movado (MOV) Higher on Upgrade Apr 16, 2008 09:21AM

StreetInsider.com Pre-Open Movers:

POZEN Inc. (Nasdaq: POZN) 44% HIGHER; GlaxoSmithKline (NYSE: GSK) and POZEN announced today that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines pioneered by GSK, and an anti-inflammatory pain reliever in a single tablet

Source Interlink Companies, Inc. (Nasdaq: SORC) 36% HIGHER; reports Q EPS of $0.20, versus $0.18 last year. Revenues for the quarter rose 47.3% to $706.4 million, versus the consensus of $602.5 million.

CV Therapeutics, Inc. (Nasdaq: CVTX) 20% HIGHER; announced that TPG-Axon Capital has agreed to pay CV Therapeutics up to $185 million in exchange for rights to ...




Apr 15, 2008 06:12PM After-Hours Movers 4/15: Intel (INTC) Up on Results, CV Therapeutics (CVTX) Higher After Selling Drug Rights
Apr 15, 2008 04:23PM CV Therapeutics (CVTX) to Receive $185 Million From TPG-Axon Capital for Half of Royalty for Lexiscan Injection
Apr 15, 2008 04:07PM CV Therapeutics (CVTX) Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Jan 8, 2008 01:26PM TPG-Axon Capital Discloses 5.5% Stake in Goodyear Tire (GT)